Summary
58 / 100 · Bulios Score
What speaks for it
- Revenue grew by 45% a year over the last 3 years.
- It holds more cash than debt: $175.7M against $8.90M.
- Analysts expect revenue to grow by 47% this fiscal year.
- Out of every 100 USD of revenue, 22 USD is left as free cash.
What to watch
- Earnings per share fell by 34% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 76.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 45% a year over the last 3 years. For the next fiscal year analysts expect revenue to grow by 47%. Earnings per share fell by 34% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 46 USD
- Research and development 15 USD
- Sales and administration 27 USD
- Taxes and other 2.3 USD
- Net profit 9.6 USD
Net profit, industry median (Medical - Pharmaceuticals) 4.8 USD
Out of every 100 USD of revenue, 9.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $86.4 is 8.7% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 100%
By region
The company reports no revenue by region.
Product brings in 100% of revenue.
Segments in detail